Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment
European Journal of Clinical Microbiology & Infectious Diseases · 2024
DOI: 10.1007/s10096-024-04892-x ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von Tsung-Ta Chiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri- Service General Hospital, National Defense Medical Cente…. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Sulbactam, Klebsiella Infections, Bacteremia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tri-Service General Hospital, National Science and Technology Council, National Defense Medical Center.
Abstract (Originalsprache)
Background
Infections caused by Klebsiella pneumoniae are common and result in high mortality rates. In vitro studies demonstrated the potency of cefoperazone/sulbactam (CPZ/SUL) against Klebsiella pneumoniae . However, the clinical efficacy of CPZ/SUL for the treatment of K. pneumoniae bacteremia has not been studied.
Objectives
This study aimed to associate the clinical outcomes of patients with bacteremia with the minimal inhibitory concentrations (MICs) of CPZ/SUL against the causative K. pneumoniae isolates.
Methods
This multicenter, retrospective study was conducted in Taiwan between July 2017 and April 2021. Patients with K. pneumoniae bacteremia treated with CPZ/SUL were enrolled in this study. CPZ/SUL MICs were determined using the agar dilution method. Data on the patients’ clinical outcomes and characteristics were collected and analyzed.
Results
In total, 201 patients were enrolled. Among the causative K. pneumoniae isolates, 180 (89.5%) were susceptible to CPZ/SUL. Most patients ( n = 156, 77.6%) had favorable outcomes. The 30-day mortality rate was 11.9% ( n = 24). Multivariate risk analyses showed that higher APACHE II score (Odds Ratio [OR], 1.14; Confidence Interval [CI], 1.07–1.21; p < 0.001), metastatic tumors (OR, 5.76; CI, 2.31–14.40; p < 0.001), and causative K. pneumoniae CPZ/SUL MICs > 16 µg/ml (OR, 4.30; CI, 1.50–12.27; p = 0.006) were independently associated with unfavorable outcomes.
Conclusion
Patients with K. pneumoniae bacteremia treated with CPZ/SUL at a ratio 1:1 had favorable outcomes when the CPZ/SUL MICs were ≤ 16 µg/ml. Patients with higher APACHE II scores and metastatic tumors had unfavorable outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri- Service General Hospital, National Defense Medical Center, No. 325, Section 2, Cheng-Kung Road, Taipei, 11490, Taiwan.
- Department of Nutritional Sciences, Fu-Jen Catholic University, New Taipei City, Taiwan.
- Institute of Biology and Anatomy, National Defense Medical Center, Tipei, Taiwan.
- Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Förderung
- Tri-Service General Hospital
- National Science and Technology Council
- National Defense Medical Center
Zitieren
APA
Chiang, T. T., Chiang, M. H., Tang, H. J., Shi, Z. Y., Ho, M. W., Chou, C. H., Lin, S. Y., Lu, P. L., Wu, T. S., Shie, S. S., Liu, J. W., Chang, F. Y., Chuang, Y. C., Wang, F. D., & Yang, Y. S. (2024). Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04892-x
Vancouver
Chiang TT, Chiang MH, Tang HJ, Shi ZY, Ho MW, Chou CH, et al. Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04892-x
BibTeX
@article{Chiang2024,
author = {Chiang, Tsung-Ta and Chiang, Ming-Hsien and Tang, Hung-Jen and Shi, Zhi-Yuan and Ho, Mao-Wang and Chou, Chia-Hui and Lin, Shang-Yi and Lu, Po-Liang and Wu, Ting-Shu and Shie, Shian-Sen and Liu, Jien-Wei and Chang, Feng-Yee and Chuang, Yin-Ching and Wang, Fu-Der and Yang, Ya-Sung},
title = {Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2024},
doi = {10.1007/s10096-024-04892-x}
}
EUVIMED